Tekmira Conference Call and Webcast Advisory: Corporate Update and Third Quarter 2012 Results
12 nov. 2012 22h35 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 12, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Tekmira and Alnylam Restructure Relationship and Settle All Litigation
12 nov. 2012 20h10 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 12, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM) today announced that it has entered into a settlement agreement with Alnylam...
Tekmira Provides Update on Collaboration With U.S. Government's TMT Program
02 oct. 2012 20h02 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Oct. 2, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today disclosed...
Tekmira Provides Update on Collaboration With U.S. Government's TMT Program
27 sept. 2012 18h20 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Sept. 27, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today...
Tekmira Provides Periodic Update to Shareholders Regarding Litigation
26 sept. 2012 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Sept. 26, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed...
Tekmira Amends Terms of $3 Million Credit Facility Providing Further Financial Flexibility
25 sept. 2012 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Sept. 25, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced it...
Tekmira Provides Periodic Update to Shareholders Regarding Litigation
19 sept. 2012 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Sept. 19, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided...
Tekmira Provides Update on Collaboration With U.S. Government's TMT Program
31 août 2012 16h30 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Aug. 31, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Tekmira Provides Corporate Update and Announces Second Quarter 2012 Results
14 août 2012 16h00 HE
|
Arbutus Biopharma Corporation
Tekmira Reports New Interim Clinical Data From TKM-PLK1 Oncology Phase 1 Clinical Trial
Conference Call at 4:30 pm Eastern Time Today
VANCOUVER, B.C., Aug. 14, 2012 (GLOBE NEWSWIRE) -- Tekmira...
Tekmira Conference Call and Webcast Advisory: Corporate Update and Second Quarter 2012 Results
09 août 2012 17h53 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Aug. 9, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...